TYK2 and systemic lupus erythematosus: Recent studies have indicated promising outcomes about the efficacy of TYK2 inhibitors in SLE and IBD treatment via blocking the IL-12, IL-23, and IFN-I pathways in animal models with short-term safety profile in human 26,27.